Roche helped by diversity

Country

Switzerland

Roche, a company whose oncology portfolio traditionally drives sales, saw growth in the first quarter from several different therapy types. Although a decline in sales of Covid-19 products pulled revenue in the diagnostic division down, the pharma division continued to advance. Diagnostics had sales of CHF 3.6 billion, down by 31% in Swiss francs from a year earlier, but pharma had sales of CHF 11.7 billion, up by 5%. The sharp fall in diagnostic sales drove group sales down by 7% to CHF 15.3 billion ($17.1 billion).